EP Patent

EP1794126A1 — Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms

Assigned to Acadia Pharmaceuticals Inc · Expires 2007-06-13 · 19y expired

What this patent protects

Disclosed herein are methods for synthesizing N-(4-fluorobenzyl -N-(I-methylpiperidin­)4-yl)-N'-(442-methylpropyloxy)-phenylmethyl)carbamide, Formula (I). Also disclosed herein is the hemi­tartrate salt of N-(4-fluorobenzyl)-N-(I-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)­ph…

USPTO Abstract

Disclosed herein are methods for synthesizing N-(4-fluorobenzyl -N-(I-methylpiperidin­)4-yl)-N'-(442-methylpropyloxy)-phenylmethyl)carbamide, Formula (I). Also disclosed herein is the hemi­tartrate salt of N-(4-fluorobenzyl)-N-(I-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)­phenylmethyl)carbamide and methods for obtaining the salt. Further disclosed are various crystalline forms of N-(4-fluorobenzyl)-N-(I-methylpiperidin-4-yl)-N'-(4-(2-metylpropyloxy)-phenymethyl)carbamide and its hemi-tartrate salt including various polymorphs and solvates.

Drugs covered by this patent

Patent Metadata

Patent number
EP1794126A1
Jurisdiction
EP
Classification
—
Expires
2007-06-13
Drug substance claim
No
Drug product claim
No
Assignee
Acadia Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.